Trial Profile
An Open-Label, Non-Inferiority Study Evaluating the Efficacy and Safety of Two Injection Schedules of Xeomin (incobotulinumtoxinA) [Short Flex Versus Long Flex] in Subjects With Cervical Dystonia With < 10 Weeks of Benefit From OnabotulinumtoxinA Treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Nov 2022
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Torticollis
- Focus Therapeutic Use
- Acronyms CD Flex
- Sponsors Merz Pharma; Merz Pharmaceuticals
- 26 Apr 2022 Results assessing the impact of 2 different injection schedules of incobotulinumtoxin A on patient-reported assessments in cervical dystonia (CD) presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 26 Apr 2022 Results presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 22 Sep 2021 Primary endpoint has been met. (Change From Baseline in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Severity Subscale Score Based on Blinded Rater Assessment at Week 4 After the 8th Injection), as per Results presented at the 25th International Congress of Parkinson's Disease and Movement Disorders